

## **Health-Economic Evaluation in Germany and Update on COPD Screening Study**

**Brisbane, Australia, 2 June 2020** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that a German hospital will perform a health-economic evaluation of ResAppDx-EU and also provided an update on its Indigenous Australian chronic obstructive pulmonary disease (COPD) screening clinical study.

### **Approval for health-economic evaluation in Germany**

Sana Klinikum Lichtenberg has recently obtained ethics approval for a pilot evaluation of ResAppDx-EU. Sana Klinikum Lichtenberg is a hospital in the German private hospital network which signed a letter of intent with ResApp for a pilot evaluation in April 2018. The pilot study will include an initial workflow assessment and quality assurance cohort of 50 subjects, followed by recruitment of up to 300 subjects to establish a baseline for the resource usage and costs associated with current care pathways for respiratory diagnosis in a German emergency department, and also compare the accuracy of ResAppDx-EU to a clinical diagnosis.

With the COVID-19 pandemic still having a major impact on healthcare globally, recruitment for the evaluation will be delayed until the demand placed on the study site from the pandemic has subsided. ResApp will provide a further update when recruitment in the study begins.

### **Update on COPD screening in Indigenous Australians study**

ResApp announced on 19 December 2019 that it had received ethics approval for a pilot, double-blind study of its COPD screening smartphone application in an Indigenous Australian population. Since December, study site start-up has progressed, with the clinical trial research agreement signed, the study registered on the Australian New Zealand Clinical Trials Registry (ANZCTR), electronic data capture systems readied, and standard operating procedures provided. Due to COVID-19 restrictions limiting access to the facility, recruitment in the study has not yet started and ResApp will provide a further update when recruitment begins.

###

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory



disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

**Contacts for ResApp Health**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*